In this free webinar, gain insight into the Parkinson’s disease therapeutic market landscape and pipeline. The featured speakers will discuss how to collaborate with patient advocacy groups effectively. Attendees will learn about employing unique study design strategies. The speakers will also share insights about protecting study endpoints to ensure clean, conclusive results.
TORONTO, Aug. 27, 2025 /PRNewswire/ — Parkinson’s disease (PD) affects more than 6 million people worldwide, yet the gold-standard treatment was approved over 30 years ago.1,2 With a robust early-stage pipeline, the absence of new, transformative treatments is not the result of a lack of interest but of the high failure rate following Phase II clinical trials.3 So, how can developers increase their probability of success?
To propel the field toward its next breakthrough, success hinges on trial designs that reflect the complexities of PD and accommodate the varying needs of patients.
In this webinar, the featured speakers will explore essential strategies for executing successful PD clinical trials. Topics will include collaborating with patient advocacy groups, using innovative study designs, selecting the appropriate symptom scales and protecting study endpoints. At the heart of it all: putting the patient first.
Register for this webinar to learn how to improve success in PD clinical trials through patient-centric and data-driven design.
Join experts from Premier Research, Antonio Hernandez, PsyD, Vice President, Program Strategy, Neuroscience; and Melissa Snyder, PhD, Executive Director, Program Strategy, Neuroscience, for the live webinar on Tuesday, September 16, 2025, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Advancing the Next Parkinson’s Disease Breakthrough: Keys to Successful Clinical Trials.
Reference:
- The Michael J. Fox Foundation for Parkinson’s Research. (2025). Parkinson’s 101. https://www.michaeljfox.org/parkinsons-101
- BioSpace. (2024, December 10). 7 most promising drugs in Parkinson’s disease treatment pipeline. https://www.biospace.com/press-releases/7-most-promising-drugs-in-parkinsons-disease-treatment-pipeline
- McFarthing, K., Buff, S., Rafaloff, G., Pitzer, K., Fiske, B., Navangul, A., Beissert, K., Pilcicka, A., Fuest, R., Wyse, R. K., & Stott, S. R. W. (2024). Parkinson’s disease drug therapies in the clinical trial pipeline: 2024 update. Journal of Parkinson’s Disease, 14(5), 899–912. https://doi.org/10.3233/JPD-240272
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit www.xtalks.com
For information about hosting a webinar, visit www.xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
SOURCE Xtalks
